Skip to main content
. 2024 May 22;10(11):e31695. doi: 10.1016/j.heliyon.2024.e31695

Fig. 6.

Fig. 6

Prognostic value of P4HA3 expression in clinical CRC patients. (A) OS of patients with CRC with low and high P4HA3 expression in TMA after 5, 7, and 10 years, and at the end of follow-up. (B) The OS of patients with CRC with low and high P4HA3 expression within each subgroup. (C) Prognostic impact of P4HA3 and PD-1 co-expression. (D) Time-related ROC. (E) Results of a Cox one-way univariate analysis in the form of a forest plot.